CL2020002768A1 - Métodos de diagnóstico de enfermedades mediante citometría de microflujos - Google Patents

Métodos de diagnóstico de enfermedades mediante citometría de microflujos

Info

Publication number
CL2020002768A1
CL2020002768A1 CL2020002768A CL2020002768A CL2020002768A1 CL 2020002768 A1 CL2020002768 A1 CL 2020002768A1 CL 2020002768 A CL2020002768 A CL 2020002768A CL 2020002768 A CL2020002768 A CL 2020002768A CL 2020002768 A1 CL2020002768 A1 CL 2020002768A1
Authority
CL
Chile
Prior art keywords
methods
μfcm
disease
diagnosing diseases
disclosed
Prior art date
Application number
CL2020002768A
Other languages
English (en)
Inventor
John Lewis
Robert Paproski
Desmond Pink
Catalina Vasquez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002768A1 publication Critical patent/CL2020002768A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1431—Signal processing the electronics being integrated with the analyser, e.g. hand-held devices for on-site investigation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G06N20/10—Machine learning using kernel methods, e.g. support vector machines [SVM]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G06N20/20—Ensemble learning
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/09—Supervised learning
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/0985—Hyperparameter optimisation; Meta-learning; Learning-to-learn
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N5/00—Computing arrangements using knowledge-based models
    • G06N5/01—Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N2015/0038—Investigating nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1488—Methods for deciding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/045—Combinations of networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/12—Computing arrangements based on biological models using genetic models
    • G06N3/126—Evolutionary algorithms, e.g. genetic algorithms or genetic programming
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Software Systems (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Computing Systems (AREA)
  • Mathematical Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Evolutionary Computation (AREA)
  • General Engineering & Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Computational Linguistics (AREA)
  • Signal Processing (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se revelan los métodos de diagnóstico de enfermedades, como el cáncer de próstata clínicamente significativo, en un paciente. También se revelan los métodos para identificar la firma de una enfermedad. Los métodos incluyen la citometría de microflujos (µFCM) para identificar los fenotipos de las partículas y luego utilizar el aprendizaje por máquina para determinar si el paciente tiene la enfermedad de interés o los fenotipos de las partículas de una enfermedad de partículas. El flujo de trabajo de análisis de µFCM que se revela aquí ayuda a identificar la información más útil desde el punto de vista clínico dentro de los datos de µFCM que pueden pasarse por alto en el análisis de compuertas convencional.
CL2020002768A 2018-04-27 2020-10-26 Métodos de diagnóstico de enfermedades mediante citometría de microflujos CL2020002768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3003032A CA3003032A1 (en) 2018-04-27 2018-04-27 Methods of diagnosing disease using microflow cytometry

Publications (1)

Publication Number Publication Date
CL2020002768A1 true CL2020002768A1 (es) 2021-05-28

Family

ID=68293427

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002768A CL2020002768A1 (es) 2018-04-27 2020-10-26 Métodos de diagnóstico de enfermedades mediante citometría de microflujos

Country Status (9)

Country Link
US (1) US20210048383A1 (es)
EP (1) EP3785014B1 (es)
JP (1) JP7451424B2 (es)
CN (1) CN112313497A (es)
AU (1) AU2019259581B2 (es)
BR (1) BR112020021779B1 (es)
CA (2) CA3003032A1 (es)
CL (1) CL2020002768A1 (es)
WO (1) WO2019204940A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220292363A1 (en) * 2019-09-02 2022-09-15 Phil Rivers Technology, Ltd. Method for automatically determining disease type and electronic apparatus
JP7428505B2 (ja) * 2019-11-19 2024-02-06 富士レビオ株式会社 コンピュータプログラム、学習モデル生成方法及び情報処理装置
CN113218848B (zh) * 2021-04-30 2022-08-12 天津深析智能科技发展有限公司 一种判断非特异细胞群的方法
CN113380318B (zh) * 2021-06-07 2023-04-07 天津金域医学检验实验室有限公司 人工智能辅助流式细胞术40cd免疫表型检测方法及系统
CN114018789A (zh) * 2021-10-08 2022-02-08 武汉大学 基于成像流式细胞检测和机器学习的急性白血病分型方法
CN115294191B (zh) * 2022-10-08 2022-12-27 武汉楚精灵医疗科技有限公司 基于电子内镜的标志物尺寸测量方法、装置、设备及介质
JP2024157876A (ja) * 2023-04-26 2024-11-08 株式会社日立ハイテク 情報処理システム、及び情報処理方法
WO2025255587A1 (en) * 2024-06-07 2025-12-11 Kohler Co. Systems and methods for generating individual health and wellness insights

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025128A (en) * 1994-09-29 2000-02-15 The University Of Tulsa Prediction of prostate cancer progression by analysis of selected predictive parameters
US6140065A (en) * 1997-09-05 2000-10-31 Dianon Systems, Inc. Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm
CA2403874A1 (en) * 2000-03-28 2001-12-06 Dana-Farber Cancer Institute, Inc. Molecular database for antibody characterization
US20040265874A1 (en) * 2000-10-17 2004-12-30 Bio-Rad Laboratories, Inc. Pattern recognition method for diagnosis of systemic autoimmune diseases
US20050095611A1 (en) * 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
US20060195266A1 (en) * 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US20070009970A1 (en) * 2005-07-08 2007-01-11 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20070255113A1 (en) * 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
WO2008064336A2 (en) * 2006-11-22 2008-05-29 Inivitrogen Corporation Autoimmune disease biomarkers
JP2010256132A (ja) * 2009-04-23 2010-11-11 Okayama Univ 糖尿病性腎症の進行度の検出方法及び糖尿病性腎症の進行度の診断キット並びに糖尿病性腎症の進行度の指標となる物質及びその選別方法
AU2012223288B2 (en) * 2011-03-01 2017-03-30 Yale University Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
US20130095575A1 (en) * 2011-10-03 2013-04-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for Fractionation, Analysis and Collection of Microvesicles From Patient Samples
MX351626B (es) * 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
CA2870835C (en) * 2012-04-19 2020-06-16 Hon Sing LEONG Method for detecting or monitoring prostate cancer
WO2014028494A1 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Detecting and treating liver damage
CN105101970B (zh) * 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
CN105764490B (zh) * 2013-09-24 2020-10-09 加利福尼亚大学董事会 用于生物测定和诊断的胶囊封装的传感器和感测系统及其制造和使用方法
EA037503B1 (ru) * 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
JP2018505392A (ja) * 2014-12-10 2018-02-22 ネオゲノミクス ラボラトリーズ, インコーポレイテッド 自動化されたフローサイトメトリ分析方法及びシステム
KR20180030549A (ko) * 2015-07-22 2018-03-23 미노믹 인터내셔널 리미티드 전립선 질병을 위한 바이오마커 조합
WO2017053592A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Deep learning in label-free cell classification and machine vision extraction of particles
AU2017235661B2 (en) * 2016-03-18 2023-06-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
CA3021036A1 (en) * 2016-04-15 2017-10-19 Octave Bioscience, Inc. Methods for assessment of multiple sclerosis activity
US10914748B2 (en) * 2016-09-08 2021-02-09 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
US10874610B2 (en) * 2016-10-19 2020-12-29 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
US9934364B1 (en) * 2017-02-28 2018-04-03 Anixa Diagnostics Corporation Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis

Also Published As

Publication number Publication date
EP3785014A1 (en) 2021-03-03
WO2019204940A1 (en) 2019-10-31
AU2019259581B2 (en) 2024-10-17
EP3785014B1 (en) 2025-06-25
CN112313497A (zh) 2021-02-02
AU2019259581A1 (en) 2020-11-26
CA3050256A1 (en) 2019-10-27
BR112020021779A2 (pt) 2021-02-23
CA3050256C (en) 2023-09-05
EP3785014A4 (en) 2022-01-26
US20210048383A1 (en) 2021-02-18
CA3003032A1 (en) 2019-10-27
BR112020021779B1 (pt) 2023-03-07
JP7451424B2 (ja) 2024-03-18
JP2021522503A (ja) 2021-08-30

Similar Documents

Publication Publication Date Title
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112015023883A2 (pt) método para avaliar planos de tratamento para a aplicação de radioterapia a um paciente; mídia não transitória legível por computador; e sistema para avaliar um plano de tratamento por radiação
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
Mirayani et al. TRANSFORMATIONAL, AUTHENTIC, AND AUTHORITARIAN TYPES OF LEADERSHIP: WHICH ONE IS THE MOST INFLUENTIAL IN STAFFS’PERFORMANCE (A Study On Performance In A Religious School Setting)
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
AR101549A1 (es) Sistema y método para informar sobre la calidad de un perforador direccional
AR092423A1 (es) Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas
Gariboldi et al. Evaluation of surgical aid of methylene blue in addition to intraoperative gamma probe for sentinel lymph node extirpation in 116 canine mast cell tumors (2017–2022)
IN2013MU01495A (es)
Pentenero et al. Microbiopsy a first‐level diagnostic test to rule out oral dysplasia or carcinoma in general dental practice
Liu et al. Deep learning based multi-organ segmentation and metastases segmentation in whole mouse body and the cryo-imaging cancer imaging and therapy analysis platform (CITAP)
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
Siegel et al. Evaluation of the vulvar cancer histology code reported by central cancer registries: importance in epidemiology
Sarkar et al. The case for microcredit: does It improve maternal and child health and wellbeing
Murray et al. Human epidermal growth factor receptor 2 testing by fluorescent in situ hybridization: positive or negative? American Society of Clinical Oncology/College of American Pathologists guidelines 2007, 2013, and 2018
Mibtadin THE URBAN SUFISM, SOCIAL MOVEMENT AND THE ‘SMILING’ISLAM: A case study of “Hubbun Nabi” Kartasura, Sukoharjo
CL2022000817A1 (es) Dispositivo de clasificación automatizada de organismos y método de uso
DE602006018458D1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
Mehrotra et al. Integrated Cancer Screening Strategies in India
Hills et al. A prospective study into the incidence of aspiration and dysphagia in acute stroke patients admitted to Beaumont Hospital
Galetta et al. Validation of multiplex immunofluorescence for use in analysis of tumour infiltrating lymphocytes
Seidl Evidence-Based and Data-Driven Approaches to Corporate Health Management
Wu et al. Advancements in Image-Based Artificial Intelligence in the Diagnosis and Treatment of Head and Neck Squamous Cell Carcinoma: A Narrative Review
Thompson Guest editorial: Furthering our understanding of positive urine cultures in dogs